https://www.indianpharmapost.com/biofrontera-scores-fda-filing-acceptance-for-ameluz-pdt-in-skin-cancer-breakthrough-191152026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/centivax-launches-first-human-trial-of-universal-flu-vaccine-191232026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/lyell-immunopharma-launches-groundbreaking-phase-3-car-t-cell-trial-for-aggressive-lymphoma-191222026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/bridgebio-reports-breakthrough-results-in-phase-3-achondroplasia-trial-191212026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/lundbecks-bocunebart-shows-breakthrough-potential-in-migraine-prevention-191202026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/amgen-scores-eu-nod-for-uplizna-in-rare-autoimmune-disease-191192026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/clinigen-bags-japans-nod-to-human-milk-based-medicine-for-preterm-infants-191182026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/stada-bio-thera-bag-european-nod-for-gotenfia-191172026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/dewpoint-therapeutics-selects-groundbreaking-myc-development-candidate-191162026-02-16T00:00:00+05:30always0.9https://www.indianpharmapost.com/agilents-pd-l1-test-gains-fda-nod-for-ovarian-cancer-191242026-02-16T00:00:00+05:30always0.9